These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7730477)

  • 21. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro induction of a Haemophilus influenzae type b polysaccharide-specific antibody response in human peripheral blood lymphocytes of individuals recently vaccinated with an oligosaccharide-protein conjugate.
    Peeters CC; Tenbergen-Meekes AM; Heijnen CJ; Poolman JT; Zegers BJ; Rijkers GT
    J Immunol; 1991 Dec; 147(12):4192-9. PubMed ID: 1753096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.
    Hetherington SV; Patrick CC
    Infect Immun; 1992 Jan; 60(1):19-24. PubMed ID: 1729183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination.
    Goldblatt D; Richmond P; Millard E; Thornton C; Miller E
    J Infect Dis; 1999 Aug; 180(2):538-41. PubMed ID: 10395878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of the immunogenicity and safety of conjugated Hemophilus influenzae type b vaccines in the elderly.
    Kantor E; Luxenberg JS; Lucas AH; Granoff DM
    Vaccine; 1997 Feb; 15(2):129-32. PubMed ID: 9066028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study.
    Togashi T; Mitsuya N; Kogawara O; Sumino S; Takanami Y; Sugizaki K
    Vaccine; 2016 Aug; 34(38):4635-4641. PubMed ID: 27265451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants.
    Chung GH; Kim KH; Daum RS; Insel RA; Siber GR; Sood S; Gupta RK; Marchant C; Nahm MH
    Infect Immun; 1995 Nov; 63(11):4219-23. PubMed ID: 7591050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation.
    Sood SK; Daum RS
    Pediatrics; 1990 Apr; 85(4 Pt 2):698-704. PubMed ID: 2107522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants.
    Kale KL; King JC; Farley JJ; Vink PE; Cimino CO; Paradiso PR
    Pediatr Infect Dis J; 1995 May; 14(5):350-4. PubMed ID: 7638008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection.
    Townsend K; Ladhani SN; Findlow H; Borrow R
    Vaccine; 2014 Sep; 32(43):5650-6. PubMed ID: 25138290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of serum bactericidal and antibody titers induced by two Haemophilus influenzae type b conjugate vaccines: A phase III randomized double-blind study.
    Akeda Y; Koizumi Y; Takanami Y; Sumino S; Hattori Y; Sugizaki K; Mitsuya N; Oishi K
    Vaccine; 2018 Mar; 36(12):1528-1532. PubMed ID: 29459064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies prevalence against Haemophilus influenzae type b in Jeddah population, Saudi Arabia. III. Antibodies avidity.
    Zarei AE; Redwan EM
    Hum Antibodies; 2019; 27(1):13-22. PubMed ID: 30103310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.
    Nolan T; Lambert S; Roberton D; Marshall H; Richmond P; Streeton C; Poolman J; Boutriau D
    Vaccine; 2007 Dec; 25(51):8487-99. PubMed ID: 17996996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia.
    Mulholland K; Suara RO; Siber G; Roberton D; Jaffar S; N'Jie J; Baden L; Thompson C; Anwaruddin R; Dinan L; Glezen WP; Francis N; Fritzell B; Greenwood BM
    JAMA; 1996 Apr; 275(15):1182-8. PubMed ID: 8609686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys.
    Peeters CC; Evenberg D; Hoogerhout P; Käyhty H; Saarinen L; van Boeckel CA; van der Marel GA; van Boom JH; Poolman JT
    Infect Immun; 1992 May; 60(5):1826-33. PubMed ID: 1563770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.